NICO Corporation, in partnership with Emory University, was set to announce the results of their seven-year multi-site clinical trial, ENRICH, evaluating the surgical treatment of intracerebral hemorrhage (ICH) with NICO’s BrainPath and Myriad tools. As the first surgical trial for ICH to meet its primary safety and efficacy endpoints, NICO was looking for ways to educate its target audience on the results with as much coverage as possible.
CLYDE leveraged the largest gathering of neurosurgeons (the Annual Meeting of the American Association of Neurological Surgeons) to build awareness of the ENRICH results among NICO’s audience. With a targeted, multi-channel communications strategy, including conference presence and collaboration with trial investigators from Emory University and the Cleveland Clinic, we ignited the conversation among key opinion leaders and positioned neurosurgeons as champions of NICO’s technology to improve patient outcomes in intracerebral hemorrhage (ICH).
CLYDE created surround sound support for NICO’s announcement at AANS to resonate with the neurosurgery community. This included leveraging a countdown video and giveaways at the booth, placements in the top media neuroscience trades, including Healio Neurology, Medscape, and Neurology Live, organic social content, and a press release sharing the topline results.
CLYDE was able to ensure news about the ENRICH trial reached our target neurosurgeon audience across multiple channels. In addition to the over 13 million media impressions from our earned placements, our integrated efforts resulted in over 70 organic social posts from the community about the positive trial results and NICO’s presence at the event, reaching an audience of over 30k followers in our target community.